MetaVia (MTVA) Restructuring Costs (2024 - 2026)
MetaVia's (MTVA) quarterly Restructuring Costs came in at $381000.0 in Q4 2025, up 36.07% YoY from $280000.0 in Q4 2024, and up 74.77% on a QoQ basis from $218000.0 in Q3 2025.
MetaVia (MTVA) Restructuring Costs (2024 - 2026) Analysis & Trends
MetaVia (MTVA) has 2 years of Restructuring Costs data on file, last reported at $381000.0 in Q4 2025.
- Quarterly Restructuring Costs rose 36.07% year-over-year to $381000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $948000.0 (changed N/A YoY) and the FY2025 annual result came in at $948000.0, down 22.36% from the prior year.
- Restructuring Costs advanced to $381000.0 in Q4 2025, from $218000.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $381000.0 in Q4 2025 to a low of $141000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 247,000.00 |
| Dec 31, 2025 | 381,000.00 |
| Sep 30, 2025 | 218,000.00 |
| Jun 30, 2025 | 141,000.00 |
| Mar 31, 2025 | 208,000.00 |
| Dec 31, 2024 | 280,000.00 |
| Sep 30, 2024 | 349,000.00 |
| Jun 30, 2024 | 223,000.00 |